ASX to rise; workplace culture, climate change in focus – Yahoo Finance Australia

Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021. We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical…

Click here to view the original article.